Compounds > yttrium radioisotopes
Page last updated: 2024-08-26

yttrium radioisotopes and Body Weight

yttrium radioisotopes has been researched along with Body Weight in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's5 (62.50)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aung, W; Furukawa, T; Kouda, K; Kurosawa, Y; Saga, T; Sudo, H; Sugyo, A; Tsuji, AB; Ukai, Y1
Baechler, S; Bischof-Delaloye, A; Hobbs, RF; Prideaux, AR; Recordon, M; Sgouros, G1
Chen, X; Jia, B; Jin, X; Li, F; Liu, Y; Liu, Z; Wang, F; Zhao, H1
Cardillo, TM; Gold, DV; Modrak, DE; Schutsky, K1
Mårtensson, L; Nilsson, R; Ohlsson, T; Senter, P; Sjögren, HO; Strand, SE; Tennvall, J; Wang, Z1
Brechbiel, MW; Burns, LJ; Panoskaltsis-Mortari, A; Sicheneder, AR; Taras, EP; Vallera, DA; Vallera, JA1
DeNardo, GL; DeNardo, SJ; Fand, I; Kroger, LA; Kukis, DL; Meares, CF; Miers, LA; Renn, O; Salako, Q; Shen, S1
DeNardo, GL; DeNardo, SJ; Kukis, DL; Lamborn, KR; Meyers, FJ; Miers, L; O'Donnell, RT1

Other Studies

8 other study(ies) available for yttrium radioisotopes and Body Weight

ArticleYear
Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody.
    Oncotarget, 2016, Jun-21, Volume: 7, Issue:25

    Topics: Animals; Antibodies, Monoclonal; Body Weight; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Integrin alpha6beta4; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Positron-Emission Tomography; Radioimmunotherapy; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2016
Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.
    Cancer biotherapy & radiopharmaceuticals, 2008, Volume: 23, Issue:5

    Topics: Antibodies, Monoclonal; Body Weight; Female; Humans; Kidney; Kinetics; Neoplasms; Radiation Dosage; Radioimmunotherapy; Radiometry; Radionuclide Imaging; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Whole Body Imaging; Yttrium Radioisotopes

2008
Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Body Weight; Cell Line, Tumor; ErbB Receptors; Fluorescent Antibody Technique; Gamma Cameras; Head and Neck Neoplasms; Humans; Mice; Organometallic Compounds; Panitumumab; Radioimmunotherapy; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2010
Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
    International journal of cancer, 2004, Apr-20, Volume: 109, Issue:4

    Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Heterocyclic Compounds; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms, Experimental; Organometallic Compounds; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2004
Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2

    Topics: Animals; Antibodies, Monoclonal; Biotin; Body Weight; Brain; Chelating Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Heterocyclic Compounds, 1-Ring; Leukocytes; Lutetium; Maximum Tolerated Dose; Platelet Count; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Time Factors; Yttrium Radioisotopes

2005
Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody.
    Cancer biotherapy & radiopharmaceuticals, 2007, Volume: 22, Issue:4

    Topics: Animals; Antibodies; Body Weight; Cell Line, Tumor; Chromatography, Ion Exchange; Humans; Immunotherapy; Leukocyte Common Antigens; Mice; Mice, Nude; Molecular Weight; Neoplasms; Polyethylene Glycols; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2007
Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).
    Cancer, 1994, Feb-01, Volume: 73, Issue:3 Suppl

    Topics: Animals; Blood Cell Count; Blood Platelets; Body Weight; Bone Marrow; Chelating Agents; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Mice; Mice, Inbred BALB C; Mucins; Pentetic Acid; Radioimmunotherapy; Radiotherapy Dosage; Yttrium Radioisotopes

1994
Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
    The Prostate, 2000, Aug-01, Volume: 44, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Body Weight; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds; Humans; Leukocyte Count; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Platelet Count; Prostatic Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Specific Pathogen-Free Organisms; Tumor Cells, Cultured; Whole-Body Counting; Yttrium; Yttrium Radioisotopes

2000